Is Atara Biotherapeutics Inc (ATRA) overvalued? · rev $128.9M
Atara Biotherapeutics Inc (ATRA) is a biotechnology company listed on NASDAQ.
This page asks whether Atara Biotherapeutics Inc (ATRA) looks expensive on cached numbers — not a short thesis.
Latest reported ATRA revenue for 2024-12-31 was $128.9M. Net income was -$85.4M. Revenue was up 1404.0% from 2023-12-31 to 2024-12-31. ATRA currently screens at market cap $87.1M.
ATRA currently screens at market cap $87.1M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next ATRA 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the ATRA stock page for the full model, not this heading.
Not investment advice.